硝氯酚 | 39224-48-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 硝氯酚
• 中文别名: 硝克洛劳
• 英文名称: nitroclofene
• 英文别名: 2-chloro-6-[(5-chloro-2-hydroxy-3-nitrophenyl)methyl]-4-nitrophenol
• CAS: 39224-48-1
• 化学式: C₁₃H₈Cl₂N₂O₆
• 分子量: 359.122
• InChiKey: DIRNVHCNISKNQF-UHFFFAOYSA-N

物化性质

• 沸点：
  514.7±50.0 °C(Predicted)
• 密度：
  1.683±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  132
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2908999090

反应信息

• 作为产物：
  描述：

  4-Chloro-2-(2-hydroxy-5-nitro-benzyl)-6-nitro-phenol 生成 硝氯酚
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Solvent vehicle for therapeutics and pharmaceutical composition containing it
  申请人：ACF CHEMIEFARMA NV

  公开号：EP0003382A1

  公开（公告）日：1979-08-08

  The invention relates to a solvent vehicle for therapeutics comprising a dialkyl ester of adipic acid and, optionally, DMSO, which is particularly useful for therapeutic materials having a low solubility or being insoluble in water. The invention further relates to pharmaceutical compositions which are suitable for parenteral administration, especially by intramuscular injection, comprising a therapeutically active material dissolved in said solvent vehicle. Solvent vehicles containing di-n-butyl adipate and DMSO, and, if desired, one or more adjuvants, are preferred. Particularly useful are pharmaceutical compositions for the prophylaxis and or treatment of diseases caused by internal parasites, which can be administered by intramuscular injection. A preferred embodiment of the invention is an injectable composition against distomatosis (liver fluke disease) containing proportionally 12.5 g 4,6'-dichloro-4',6-dinitro-2,2'-methylene-diphenol and 30 g of DMSO, completed with di-n-butyl adipate to 100 cm3,

  本发明涉及一种治疗用溶剂载体，由己二酸二烷基酯和可选的二甲基亚砜组成，特别适用于溶解度低或不溶于水的治疗材料。 本发明还涉及适用于非肠道给药，特别是肌肉注射的药物组合物，该组合物包含溶解在所述溶剂载体中的治疗活性物质。 溶剂载体最好含有己二酸二正丁酯和二甲基亚砜，如果需要，还可加入一种或多种佐剂。 特别有用的是用于预防和治疗由体内寄生虫引起的疾病的药物组合物，可以通过肌肉注射给药。本发明的一个优选实施方案是一种预防肝吸虫病（distomatosis）的注射组合物，按比例含有 12.5 克 4,6'-二氯-4',6-二硝基-2,2'-亚甲基-二苯酚和 30 克二甲基亚砜，并加入己二酸二正丁酯至 100 立方厘米、
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• ——
  作者：

  DOI：——

  日期：——
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13
• CONTROLLED ABSORPTION WATER-SOLUBLE PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND FORMULATION FOR ONCE-DAILY ADMINISTRATION
  申请人：STI Pharma, LLC

  公开号：EP2717860A1

  公开（公告）日：2014-04-16